https://stock.noler.com/us/stock/syros-pharmaceuticals-inc https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/accounts-payable https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/accounts-receivable https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/accretion-amortization-of-discounts-and-premiums-investments https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/accrued-professional-fees-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/accrued-rent-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/accumulated-amortization-deferred-finance-costs https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/accumulated-depreciation https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/aoci https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/asset-impairment-charges https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/assets-held-for-sale-long-lived-fair-value-disclosure https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-amortized-cost https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-debt-realized-gain-loss https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-debt-unrealized-loss-position-12-months-or-longer-loss https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-debt-unrealized-loss-position-less-than-12-months-loss https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-debt-unrealized-loss-position-less-than-12-months-number-of-positions https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-gross-realized-gain-loss-net https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-in-unrealized-loss-positions-qualitative-disclosure-number-of-positions https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-in-unrealized-loss-positions-qualitative-disclosure-number-of-positions-greater-than-or-equal-to-one-year https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-in-unrealized-loss-positions-qualitative-disclosure-number-of-positions-less-than-one-year https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-securities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-unrealized-loss-position-12-months-or-longer-loss https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-unrealized-loss-position-less-than-12-months-loss https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/available-for-sale-unrealized-loss-position-less-than-twelve-months-fair-value https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/basic-shares https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-expenditures https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-expenditures-incurred-but-not-yet-paid https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-lease-obligations-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-lease-obligations-incurred https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-lease-obligations-noncurrent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-leases-future-minimum-payments-due https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-leases-future-minimum-payments-due-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-leases-future-minimum-payments-due-in-five-years https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-leases-future-minimum-payments-due-in-four-years https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-leases-future-minimum-payments-due-in-three-years https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/capital-leases-future-minimum-payments-due-in-two-years https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/cash-and-cash-equivalents-fair-value-disclosure https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/cash-and-equivalents https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/cash-and-restricted-cash https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/cash-cash-equivalents-and-short-term-investments https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/cash-flow-breakdown https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/class-of-warrant-or-right-number-of-securities-called-by-warrants-or-rights https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/common-stock-value https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/comprehensive-income https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/contract-liability https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/contract-with-customer-asset-net-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/contract-with-customer-liability-noncurrent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/contracts-revenue https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/conversion-of-stock-amount-issued https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/convertible-preferred-stock-shares-issued-upon-conversion https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/current-assets https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/current-income-tax-expense-benefit https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/current-liabilities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/current-portion-of-long-term-debt https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/debt-carrying-amount https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/debt-issuance-costs-incurred-during-noncash-or-partial-noncash-transaction https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/debt-maturing-after-year-five https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/debt-maturing-in-year-five https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/debt-maturing-in-year-four https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/debt-maturing-in-year-three https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/debt-maturing-in-year-two https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/debt-maturing-remainder-of-fiscal-year https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/debt-unamortized-discount https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-compensation-share-based-arrangements-liability-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-income-tax-liabilities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-revenue https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-assets-deferred-income https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-assets-goodwill-and-intangible-assets https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-assets-in-process-research-and-development https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-assets-tax-credit-carryforwards https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/deferred-tax-liabilities-property-plant-and-equipment https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/defined-contribution-plan-cost-recognized https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/defined-contribution-plan-employer-discretionary-contribution-amount https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/defined-contribution-plan-employer-matching-contribution-percent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/defined-contribution-plan-employer-matching-contribution-percent-of-match https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/defined-contribution-plan-maximum-annual-contributions-per-employee-percent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/depreciation-and-amortization https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/diluted-shares https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/effective-tax-rate https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/employee-related-liabilities-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/eps https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/eps-basic https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/fair-value-adjustment-of-warrants https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-interest-expense https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-noncurrent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-payments-due https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-payments-due-in-next-rolling-twelve-months https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-payments-due-in-rolling-year-five https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-payments-due-in-rolling-year-four https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-payments-due-in-rolling-year-three https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-payments-due-in-rolling-year-two https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-payments-due-next-twelve-months https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-payments-due-year-three https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-payments-due-year-two https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-principal-payments https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-right-of-use-asset https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-right-of-use-asset-amortization https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/finance-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/financing-cash-flow https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/form-d-other https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/form-d-stocks https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/gain-loss-on-termination-of-lease https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/general-and-administrative-expense https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/impairment-of-long-lived-assets-held-for-use https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/impairment-of-long-lived-assets-to-be-disposed-of https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/incentive-from-lessor https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/income-tax https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/income-taxes-paid https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/increase-decrease-in-contract-with-customer-asset https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/increase-decrease-in-contract-with-customer-liability https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/increase-decrease-in-operating-lease-liability https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/increase-decrease-in-other-noncurrent-assets https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/increase-decrease-in-restricted-cash-for-operating-activities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/insider-transactions-other https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/insider-transactions-preferred https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/insider-transactions-stock-units https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/insider-transactions-warrants https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/insider-transactions-warrants/purchases https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/interest-expense https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/interest-expense-nonoperating https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/interest-paid https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/interest-paid-net https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/investing-cash-flow https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/investment-income-interest https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/letters-of-credit-outstanding-amount https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/liability-for-uncertain-tax-positions-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/long-term-debt https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/marketable-securities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/marketable-securities-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/marketable-securities-gain-loss-excluding-other-than-temporary-impairments https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/marketable-securities-noncurrent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/net-cash-from https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/net-cash-from-financing-activities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/net-cash-from-investing-activities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/net-cash-from-operating-activities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/net-change-in-cash https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/net-income https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/number-of-operating-segments https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/oci-available-for-sale-adjustment-net-of-tax-2 https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/oci-net-of-tax https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-cash-flow https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-expenses https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-income https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-assets https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-cost https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-expense https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-liability https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-liability-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-2 https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-leases-rent-expense-net https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/operating-loss-carryforwards https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/other-noncurrent-assets https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/paid-in-capital-warrant-issued https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/payments-to-acquire-marketable-securities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/preferred-shares-facts https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/preferred-stock-dividends-and-other-adjustments https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-debt-net-of-issuance-costs https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-issuance-of-convertible-preferred-stock https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-issuance-of-private-placement https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-issuance-of-shares-under-incentive-and-share-based-compensation-plans https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-issuance-of-shares-under-incentive-and-share-based-compensation-plans-including-stock-options https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-sale-and-maturity-of-marketable-securities https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-stock-plans https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/proceeds-from-warrant-exercises https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/profit-loss https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/property-plant-equipment https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/public-float https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/repayments-of-debt-and-capital-lease-obligations https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/repayments-of-long-term-capital-lease-obligations https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/research-and-development https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/restricted-cash-and-cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/restricted-cash-and-cash-equivalents-noncurrent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/restructuring-and-related-cost-number-of-positions-eliminated-period-percent https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/restructuring-charges https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/retained-earnings https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/revenue https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/revenues https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/severance-costs https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/shareholders-equity https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/shares-authorized https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/shares-issued https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/shares-issued-price-per-share https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-award-fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-based-compensation https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-compensation-unrecognized-cost https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-issued-shares-issued-value-espp https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-issued-shares-issued-value-restricted-stock-award-gross https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-issued-shares-issued-value-share-based-compensation-gross https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-forfeitures-and-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-vested-and-expected-to-vest-exercisable-aggregate-intrinsic-value https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-vested-and-expected-to-vest-exercisable-average-exercise-price https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/stock-redeemed-or-called-value https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/tax-rate-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/tax-rate-reconciliation-tax-credits-research https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/total-assets https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/total-contract-liability https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/total-long-term-debt https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/unbilled-receivables-current https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/utb-income-tax-penalties-accrued https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/utb-interest-on-income-taxes-accrued https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/syros-pharmaceuticals-inc/weighted-average-number-of-share-outstanding-basic-and-diluted